PITTSBURGH, Jan. 26, 2011 /PRNewswire/ -- Cohera Medical Inc. today announced that it has appointed Mart E. Pearson as vice president, Europe. Pearson will play an integral role in Cohera Medical's preparation in seeking CE Mark approval for its lead surgical adhesive product, TissuGlu.
"We have enormous opportunities for the rapid and long-term growth with our adhesive technologies, and Mart has an outstanding track record of success in launching new medical devices in the European arena," said Patrick Daly, president and CEO of Cohera Medical. "Mart understands the needs of surgeons and is experienced in developing good two-way communications with key opinion leaders. His knowledge in building sales organizations from the ground and experience in developing markets through both direct and distributor sales organizations will serve us well as we prepare for the launch of TissuGlu in the European market later this year."
Pearson has more than 20 years of experience in international sales and marketing of medical devices and has been responsible for the introduction of new products in surgical oncology, minimally invasive surgery, orthopedics, general surgery and infection prevention. Most recently, he was vice president, international, at Salient Surgical Technologies Inc. He led the introduction of the company's saline-enhanced radiofrequency product platform to the European markets and was responsible for all markets outside of the U.S. in 2005. Prior to that, he was vice president sales, Europe, and responsible for opening one of the first international subsidiaries of STERIS Corporation, where he established successfully the SYSTEM 1 low temperature liquid sterilization system as a market leader in Italy.
Pearson holds a bachelor's degree in analytic philosophy from Pomona College and has continuously pursued his interests in new market development, entrepreneurial business, languages, cross cultural communications and management. He is located in Northern Italy.
About Cohera Medical
Headquartered in Pittsburgh, Cohera Medical is actively developing a line of surgical adhesives based on polyurethane chemistry. The company's product pipeline and technology expertise are indicative of a strong R&D force that is committed to offering the best and the safest solutions to the surgeon and patient in the medical adhesive industry. Cohera completed its first human clinical trial of TissuGlu in Germany and demonstrated product safety and preliminary efficacy. The company currently has 36 pending-patent applications in the U.S. and abroad. The company's first patent was issued in June 2007 followed by successive applications covering dispenser design and adhesive material technology. TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit http://www.coheramed.com/.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
SOURCE Cohera Medical, Inc.